Iron status markers in patients with small cell carcinoma of the lung. Relation to survival.

por Milman, N., Sengeløv, H., Dombernowsky, P.
Publicado 1991

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy

por Tuxen, M K, Sölétormos, G, Dombernowsky, P
Publicado 2001

Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up.

por Osterlind, K., Hansen, H. H., Hansen, H. S., Dombernowsky, P., Hansen, M., Rørth, M.
Publicado 1986

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression

por Lassen, U N, Østerlind, K, Hirsch, F R, Bergman, B, Dombernowsky, P, Hansen, H H
Publicado 1999

Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

por Sørensen, J B, Bergman, B, Nielsen, A L, Krarup, M, Dombernowsky, P, Hansen, H H
Publicado 1999

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy

por Sigsgaard, T, Herrstedt, J, Andersen, L J, Havsteen, H, Langer, S W, Kjærbøl, A-G, Lund, H, Kjær, M, Dombernowsky, P
Publicado 1999

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.

por Nielsen, O. S., Dombernowsky, P., Mouridsen, H., Crowther, D., Verweij, J., Buesa, J., Steward, W., Daugaard, S., van Glabbeke, M., Kirkpatrick, A., Tursz, T.
Publicado 1998